924287-64-9

Basic information

• Product Name: 6-Benzothiazolecarboxylic acid, 2-aMino-4-fluoro-, Methyl ester
• Synonyms: 6-Benzothiazolecarboxylic acid, 2-aMino-4-fluoro-, Methyl ester;2-Amino-4-fluoro-6-benzothiazolecarboxylic acid methyl ester
• CAS NO: 924287-64-9
• Molecular Formula: C₉H₇FN₂O₂S
• Molecular Weight: 226.2274832
• Mol File: 924287-64-9.mol

Chemical Properties

• Boiling Point: 390℃
• Flash Point: 190℃
• Appearance: /
• Density: 1.501
• CAS DataBase Reference: 6-Benzothiazolecarboxylic acid, 2-aMino-4-fluoro-, Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Benzothiazolecarboxylic acid, 2-aMino-4-fluoro-, Methyl ester(924287-64-9)
• EPA Substance Registry System: 6-Benzothiazolecarboxylic acid, 2-aMino-4-fluoro-, Methyl ester(924287-64-9)

Safety Data

• Hazardous Substances Data: 924287-64-9(Hazardous Substances Data)

Upstream product

• 333-20-0 potassium thioacyanate 
• 185629-32-7 methyl 4-amino-3-fluorobenzene carboxylate 
• 540-72-7 sodium thiocyanide 
• 185629-31-6 methyl 3-fluoro-4-nitrobenzoate 
• 403-21-4 3-fluoro-4-nitrobenzoic acid 

Downstream Products

• 1383816-28-1 methyl-2-(3-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)-8-azabicyclo[3.2.1]octan-8-yl)-4-fluorobenzo[d]thiazole-6-carboxylate 
• 1383816-29-2 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid 
• 1383816-38-3 C₂₉H₂₆F₄N₄O₄S 
• 924287-65-0 methyl 2-bromo-4-fluoro-1,3-benzothiazole-6-carboxylate 

Relevant articles and documents

ANTIVIRAL HETEROCYCLIC COMPOUNDS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

COMPOSITIONS AND METHODS FOR TREATING LIVER DISORDERS

The present disclosure is directed to FXR agonists, pharmaceutical compositions thereof, and methods of using the same for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis, either alone or in combination with thyroid receptor agonists.

NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA

The present invention relates to compounds having a structure of general formula (I), processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in humans and warm-blooded animals.

FXR RECEPTOR AGONIST

The present invention belongs to the technical field of pharmaceuticals, and particularly relates to a compound of formula (I), a pharmaceutically acceptable salt thereof, an ester thereof or a stereoisomer of the compound, the salt or the ester, wherein

Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis

Farnesoid X receptor (FXR) plays a key role in bile acid homeostasis, inflammation, fibrosis, and metabolism of lipid and glucose and becomes a promising therapeutic target for nonalcoholic steatohepatitis (NASH) or other FXR-dependent diseases. The phase III trial results of obeticholic acid demonstrate that the FXR agonists emerge as a promising intervention in patients with NASH and fibrosis, but this bile acid-derived FXR agonist brings severe pruritus and an elevated risk of cardiovascular disease for patients. Herein, we reported our efforts in the discovery of a series of non-bile acid FXR agonists, and 36 compounds were designed and synthesized based on the structure-based drug design and structural optimization strategies. Particularly, compound 42 is a highly potent and selective FXR agonist, along with good pharmacokinetic profiles, high liver distribution, and preferable in vivo efficacy, indicating that it is a potential candidate for the treatment of NASH or other FXR-dependent diseases.

COMPOUNDS FOR MODULATING FXR

Provided herein are compounds of Formula (I), a stereoisomer, enantiomer or a pharmaceutically acceptable salt thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).

FXR receptor agonist

The present invention discloses an FXR receptor agonist, belongs to the technical field of medicine, and particularly relates to a compound represented by a formula (I), a pharmaceutically acceptablesalt, an ester or a stereoisomer thereof, wherein R, R, R, M, L, L1, W, A , B, Q, m and n are defined in the specification. The present invention further relates to a preparation method of the compound, a pharmaceutical preparation, and applications in preparation of drugs for treatment and/or prevention of nonalcoholic fatty liver disease, primary biliary cirrhosis, lipid metabolism disorder, diabetic complication, malignant tumors and other related diseases mediated by FXR receptors. The formula I is defined in the specification.

HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS

The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, A, X1

ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF

The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediate